Skip to main content

Table 1 SPIRIT schematic schedule of enrolment, interventions, and assessments

From: The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial—study protocol for a randomized controlled trial

 

Inclusion and randomization visit

Follow up visits, day 1 to day 7

End of study, day 28

Inclusion and non-inclusion criteria

X

  

Informed consent

X

X(0)

X(0)

Randomization

X

  

Medical history/comorbidities

X

X

X*

Concomitant treatment

X

X

X*

Clinical examination

X(1)

X(1)

X* (1)

Blood sample for local biological assessment

X(2)

X(2)

 

Glasgow Coma Score

X

X

X*

Assessment of SOFA score

X

X

 

Molting score (picture of skin knees)

X

X**

 

Capillary refill time

X

X

 

biological collection

X, within the 12 first hours after randomization

  

Drug intake

X(3)

X(3)

 

Retrieval of adverse events

X

X

X

Assessment of morbidity and mortality

X

X

X

  1. Intravenous administration of Ilomedin or placebo will be started at 0.5 ng/kg/min increasing every 30 min up to a maximum of 1.5 ng/kg/min for 48 h
  2. (0) If not done at the previous visits (according to law L1122-1-3 of the PHC)
  3. (1) Clinical examination:
  4. - Hemodynamic parameters: systolic, mean, and diastolic arterial pressure; heart rate; central venous pressure; central venous oxygen saturation; cardiac output if available
  5. - Electrocardiogram
  6. (2) Blood sample:
  7. - Biological parameters: arterial plasma lactate level, plasma pH and base excess, PaO2 and PaO2/FiO2, PaCO2, blood urea nitrogen, serum creatinine, serum potassium level, hemoglobin, brain natriuretic peptide (BNP) or NT-ProBNP, ultrasensitive troponin, total bilirubin level and platelet count
  8. *if the patient is still hospitalized
  9. **at inclusion and at D2
  10. (3) Drug intake: the treatment period is 48 h